Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 5/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.71 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | PTGES | O14684 | 1/20 | 0.68 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delmetacin SCHEMBL286727 | 0.91 | ABCB1 (0.82) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL13802409 | 0.90 | ABCB1 (0.81) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL14280740 | 0.89 | ABCB1 (0.80) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL2237214 | 0.89 | PTGS2 (0.80) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL6206650 | 0.88 | ABCB1 (0.79) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL6206463 | 0.87 | ABCB1 (0.77) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL13299759 | 0.87 | ABCB1 (0.79) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL26771824 | 0.87 | PTGS2 (0.77) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL4211502 | 0.86 | ABCB1 (0.76) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 | |
| SCHEMBL13802388 | 0.86 | ABCB1 (0.76) | ABCB1PTGS2PTGS1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | claimed |
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-10-21 | — | — | US | claimed |
| EP-1590314-B1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2015-08-05 | — | — | EP | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8871784-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE'S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-8648110-B2 | 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2014-02-11 | — | — | US | disclosed |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2011-08-11 | — | — | US | disclosed |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2011-08-11 | — | — | US | disclosed |
| US-7776909-B2 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPE PHA.R.MA S.P.A. (IT) | 2010-08-17 | — | — | US | disclosed |
| US-7776909-B2 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPE PHA.R.MA S.P.A. (IT) | 2010-08-17 | — | — | US | disclosed |
| US-7776909-B2 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPE PHA.R.MA S.P.A. (IT) | 2010-08-17 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2006-10-05 | — | — | US | disclosed |
| EP-1590314-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompe' S.P.A. (IT) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004069782-A2 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267726-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | ABCB1 3451/4885PTGS2 124/4885PTGS1 128/4885 |
| US-20110195967-A1 | 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, MMP8, CXCR1 | ABCB1 3425/4885PTGS2 124/4885PTGS1 129/4885 |
| US-20060223842-A1 | such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia | CXCR2, CXCR1, MMP8 | ABCB1 4043/4885PTGS2 121/4885PTGS1 52/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | ABCB1 139/4885PTGS2 2066/4885PTGS1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.